Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Welcome to the 5th Next Generation Gene Therapy Vectors Summit!
Achieve Safety through Novel Capsids & Payloads
2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between Roche and Dyno Therapeutics, which could generate more than $1 billion for Dyno, it was time to come together and unlock the ever-clearer potential of vector therapies.
The 5th Next Generation Gene Therapy Vectors Summit returned as the only vector therapy-specific platform for experts to join forces, share technical insights, transform viral and non-viral vector design and selection, and streamline translation to the clinic.
Providing an unmatched, close-knit collaborative environment created specifically with and for the gene therapy vector community, attendees connected and learned from leaders such as Spark Therapeutics, Novartis, 4D Molecular Therapeutics, Apertura Gene Therapy, and Coave Therapeutics, in a bid to discover innovative, rational vector design and AI-driven approaches. It emphasised cost- and time-effective strategies for non-clinical testing and vector manufacturing to achieve clinical validation and deliver vector therapies to more patient populations.
The 5th Next Generation Gene Therapy Vectors Summit brought together some of the brightest minds in the field.
Ahead of the event, Dr. Ralf Schmid, an Independent Consultant, sat down with Erin Harris for a powerful episode of Cell & Gene: The Podcast.
In this exclusive conversation, Dr. Schmid explored the evolving use of large animal models in gene therapy – from ethical challenges to emerging alternatives like genetically engineered pigs and sheep – and highlighted their critical role in CNS-targeted AAV research. He also shared a glimpse of what he covered at the summit.
Quick Download the Brochure Here to Explore:
10+
New Companies that Attended
20+
Expert Speakers
40+
Companies Represented
60+
Attendees to Network With
❝
I am looking forward to the Next Generation Gene Therapy Vectors Summit because it creates space for cross-functional collaboration on one of the field’s most urgent challenges - developing safe and effective vectors with efficiency. This meeting is a chance to share how regulatory approaches, capsid engineering, and translational strategies can work together to accelerate therapies for patients
Jorge Santiago-Ortiz PhD, Senior Director, CMC, Apertura Gene Therapy
❞
The Expert Speaker Faculty Included:
Previously Attending Companies:
❝
This summit is a meeting of the minds in vector biology and innovation and is a wonderful way to learn and explore novel ideas for more efficient and effective therapeutic development.
Roxanne Croze, Senior Director, Vector Innovation, 4D Molecular Therapeutics
❞
Our 2025 Partners:
